The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10623 malaria professionals are enjoying the free benefits of MalariaWorld today

Mali

Open Access | In Vitro Growth-Inhibitory Activity and Malaria Risk in a Cohort Study in Mali

January 31, 2010 - 13:03 -- Ingeborg van Schayk
Author(s): 
Peter D. Crompton, Kazutoyo Miura, Susan K. Pierce et al.
Reference: 
Infect. Immun. 2010;78 737-745 Open Access

These data suggest that antibodies which block merozoite invasion of RBC and/or inhibit the intra-RBC growth of the parasite contribute to but are not sufficient for the acquisition of malaria immunity.

Country: 
Medical Condition: 

Open Access | Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali

January 13, 2010 - 13:20 -- Ingeborg van Schayk
Author(s): 
Alassane Dicko, Issaka Sagara, Abdoulaye A Djimde, Sidy O Toure, Mariam Traore, Souleymane Dama, Abdoulbaki I Diallo, Amadou Barry, Mohamed Dicko, Oumar M Coulibaly, Christophe Rogier, Alexandra de Sousa, Ogobara K Doumbo
Reference: 
Malaria Journal 2010, 9:9 (10 January 2010)

A paper that addresses the issue of possible selection of drug resistant parasites in the context of Intermittent Preventive Treatment in infants. Importantly, this study evaluates the impact of the intervention at community level, in a context of a large scale implementation.

Person: 
Country: 
Medical Condition: 
Medical Treatment: 

A molecular map of chloroquine resistance in Mali

January 10, 2010 - 16:54 -- Ingeborg van Schayk
Author(s): 
A. A. Djimde, B. Barger, A. Kone, A. H. Beavogui, M. Tekete, B. Fofana, A. Dara, H. Maiga, D. Dembele, S. Toure, S. Dama, D. Ouologuem, C. P. O. Sangare, A. Dolo, N. Sogoba, K. Nimaga, Y. Kone & O. K. Doumbo
Reference: 
FEMS Immunology & Medical Microbiology, Early View (Articles online in advance of print)

We present a comprehensive map of CQR in Mali, which strongly supports recent changes in drug policy away from chloroquine.

Country: 
Medical Condition: 
Medical Treatment: 

Open Access | Comparative Analysis of the Global Transcriptome of Anopheles funestus from Mali, West Africa

December 15, 2009 - 20:53 -- Ingeborg van Schayk
Author(s): 
Serazin AC, Dana AN, Hillenmeyer ME, Lobo NF, Coulibaly MB, et al.
Reference: 
PLoS ONE 4(11): e7976

In aid of future genomic sequencing of An. funestus, we explored the whole body transcriptome, derived from mixed stage progeny of wild-caught females from Mali, West Africa.

Country: 
Region: 

Argemone Mexicana decoction versus artesunate-amodiaquine for the management of malaria in Mali: policy and public-health implications.

December 3, 2009 - 12:07 -- Patrick Sampao
Author(s): 
Bertrand Graz, Merlin L. Willcox, Chiaka Diakite, Jacques Falquet, Florent Dackuo, Oumar Sidibe, Sergio Giani, Drissa Diallo
Reference: 
Transactions of the Royal Society of Tropical Medicine and Hygiene, Volume 104, Issue 1, January 2010, Pages 33-41, doi:10.1016/j.trstmh.2009.07.005

A classic way of delaying drug resistance is to use an alternative when possible. We tested the malaria treatment Argemone mexicana decoction (AM), a validated self-prepared traditional medicine made with one widely available plant and safe across wide dose variations. In an attempt to reflect the real situation in the home-based management of malaria in a remote Malian village, 301 patients with presumed uncomplicated malaria (median age 5 years) were randomly assigned to receive AM or artesunate-amodiaquine [artemisinin combination therapy (ACT)] as first-line treatment.

Country: 
Medical Condition: 

Extreme Polymorphism in a Vaccine Antigen and Risk of Clinical Malaria: Implications for Vaccine Development

October 25, 2009 - 17:04 -- Bart G.J. Knols
Author(s): 
Shannon L. Takala et al.
Reference: 
Science Translational Medicine. 2009; 1:2ra5

Vaccines directed against the blood stages of Plasmodium falciparum malaria are intended to prevent the parasite from invading and replicating within host cells. No blood-stage malaria vaccine has shown clinical efficacy in humans. Most malaria vaccine antigens are parasite surface proteins that have evolved extensive genetic diversity, and this diversity could allow malaria parasites to escape vaccine-induced immunity. We examined the extent and within-host dynamics of genetic diversity in the blood-stage malaria vaccine antigen apical membrane antigen–1 in a longitudinal study in Mali. 

Technology: 
Country: 
Medical Condition: 
Medical Treatment: 

Pages

Subscribe to RSS - Mali